Results 151 to 160 of about 166,181 (302)

Stem Cell Therapy for Inflammatory Diseases: Progress, Challenges, and Future Directions

MedComm, Volume 7, Issue 2, February 2026.
Stem cells offer multifaceted therapeutic approaches for inflammatory diseases, each exhibiting distinct therapeutic properties. Hematopoietic stem cells, primarily through hematopoietic stem cell transplantation (HSCT), can effectively remodel the immune environment, showing particular promise in treating genetically linked cases.
Chen Wu, Zhi‐Ping Jin, Shu‐Qiang Weng, Ji‐Min Zhu, Ling Dong   +4 more
wiley   +1 more source

Acute collapse in a dog with multiple autoimmune syndromes and polymyositis complicated by suspected organophosphate/carbamate toxicity

Veterinary Record Case Reports, Volume 14, Issue 1, February 2026.
Abstract A 6.5‐year‐old, spayed, female dog presented in acute respiratory distress. On admission, the dog exhibited dyspnoea, bradycardia, cyanosis and gastrointestinal signs, requiring immediate intubation and mechanical ventilation. Diagnostic evaluation revealed reduced butyrylcholinesterase activity, non‐cardiogenic pulmonary oedema, elevated ...
Sarah Hefer, Efrat Kelmer, Michal Mazaki Tovi, Dana Peery, Kobi Aharoni, Nir Edry, Sigal Klainbart   +6 more
wiley   +1 more source

Comprehensive Evaluation of a Cream With Advanced Soothing Complex for Skin Recovery Following Intense Pulsed Light Therapy

Journal of Cosmetic Dermatology, Volume 25, Issue 2, February 2026.
ABSTRACT Background Intense pulsed light (IPL) therapy is widely used for skin rejuvenation but frequently induces transient skin barrier impairment, erythema, and discomfort. Post‐procedure skincare targeting barrier repair and symptom relief remains a clinical priority.
Jianhua Zhang, Shichao Liu, Wenjiao Guo, Na Li, Li Ye   +4 more
wiley   +1 more source

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

, 2020
Bathon, J., Breedveld, F., Burmester, G., Bykerk, V., Crofford, L., Cronstein, B., Dougados, M., Furst, D., Kalden, J., Mariette, X., Mease, P., Melchers, F., Rosenbaum, J., Sieper, J., Smolen, J., Weinblatt, M., Winthrop, K.   +16 more
core   +1 more source

Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus

Clinics, 2012
OBJECTIVE: To determine the serum levels of interferon alpha in childhood-onset systemic lupus erythematosus patients, their first-degree relatives and healthy controls and to evaluate the associations between serum interferon alpha and disease activity,
Mariana Postal, Nailu Angélica Sinicato, Karina Oliveira Peliçari, Roberto Marini, Lilian Tereza Lavras Costallat, Simone Appenzeller   +5 more
doaj  

Use of anifrolumab in systemic lupus erythematosus, cutaneous lupus erythematosus, and other autoimmune dermatoses.

Actas Dermo-Sifiliográficas
D. Martín-Torregrosa, M. Mansilla-Polo, D. Morgado-Carrasco   +2 more
semanticscholar   +1 more source

Cryoglobulinemia: An update on classification, pathophysiology, clinical presentation, and management

Journal of Internal Medicine, Volume 299, Issue 2, Page 196-215, February 2026.
Abstract Cryoglobulinemia (CG) is defined by the presence of serum immunoglobulins that precipitate below 37°C and redissolve upon rewarming. It is classified into three types based on immunoglobulin composition. Type I, a rare form, involves monoclonal IgM or IgG and is linked to lymphoproliferative disorders.
Anna Linda Zignego, Laura Gragnani, Marcella Visentini, Riccardo Bomben, Luca Arcaini, Clodoveo Ferri, Valter Gattei, Cesare Mazzaro   +7 more
wiley   +1 more source

Significant improvement of refractory cutaneous lesions of lupus erythematosus with the use of anifrolumab: a report of two cases

Revista da Sociedade Portuguesa de Dermatologia e Venereologia
Anifrolumab, a monoclonal antibody targeting the interferon-1 receptor, is currently approved for the treatment of moderate- to-severe systemic lupus erythematosus, but emerging evidence highlights its potential efficacy in cases with predominant ...
Gilberto P. da Rosa, Isabel Antunes, Bárbara V. Granja, Patrícia Gomes, Rúben Costa, Filomena Azevedo, Alberto Mota   +6 more
doaj  

[[Translated article]]Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses.

Actas Dermo-Sifiliográficas
D. Martín-Torregrosa, M. Mansilla-Polo, D. Morgado-Carrasco   +2 more
semanticscholar   +1 more source

Lysophosphatidic Acid Synergizes With 1,25‐Dihydroxyvitamin D to Promote Fibroblast Growth Factor‐23 Synthesis via MAPK Signaling and Induction of the IL12A Gene

The FASEB Journal, Volume 40, Issue 1, 15 January 2026.
Ay et al. investigated the cellular mechanisms behind the role of lysophosphatidic acid (LPA) in FGF23 production. They revealed that LPA cooperates with 1,25‐dihydroxyvitamin D (1,25D), that is, the bioactive form of vitamin D known to stimulate FGF23 synthesis. This synergy entails MAPK signaling and the induction of the gene encoding the interleukin‐
Birol Ay, Sajin Marcus Cyr, Yorihiro Iwasaki, Elizabeth Hill, Eugene P. Rhee, Nevil J. Singh, Petra Simic, Murat Bastepe   +7 more
wiley   +1 more source